MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma

Authors: Thomas F. Eleveld, Lindy Vernooij, Linda Schild, Bianca Koopmans, Lindy K. Alles, Marli E. Ebus, Rana Dandis, Harm van Tinteren, Huib N. Caron, Jan Koster, Max M. van Noesel, Godelieve A. M. Tytgat, Selma Eising, Rogier Versteeg, M. Emmy M. Dolman, Jan J. Molenaar

Source: Frontiers in Oncology, Vol 13 (2023)

Subject Terms: MEK, b-cell lymphoma 2 (BCL-2), neuroblastoma, trametinib (PubChem CID: 11707110), navitoclax (ABT-263, PubChem CID: 24978538), venetoclax (ABT-199, PubChem CID: 49846579), Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2023.1130034/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/f113f91a5d74419a8ac27a8cd36776b9